https://medcitynews.com/2020/09/whi...i-capability-calling-employees-dirty-indians/
The allegations against ElectrifAi and its former CEO, Edward Scott, as reported in the 2020 MedCity News article, raised significant concerns regarding the company's development and marketing of the PulmoAi tool during the height of the COVID-19 pandemic. Whistleblowers asserted that PulmoAi, intended for assessing COVID-19 severity from chest X-rays and CT scans, suffered from inadequate training data, limited clinical validation, and a lack of FDA authorization, potentially overstating its capabilities in a critical healthcare context. The company maintained that the product was legitimate and in use by select healthcare organizations, with listings on platforms such as the Azure Marketplace and AWS Marketplace persisting for years, though public evidence of widespread adoption or ongoing relevance appears minimal as of 2026.